Phenmetrazine: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 34: | Line 34: | ||
[[Category:Controlled substances]] | [[Category:Controlled substances]] | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
== Phenmetrazine == | |||
<gallery> | |||
File:Phenmetrazine.svg|Structure of Phenmetrazine | |||
File:Phenmetrazine_Synthesis.svg|Synthesis of Phenmetrazine | |||
</gallery> | |||
Latest revision as of 01:54, 17 February 2025
Phenmetrazine is a stimulant drug that was previously used as an appetite suppressant, but has since been withdrawn from the market. It was initially marketed in the 1950s. Phenmetrazine was a problem drug, and is now a controlled substance in many countries due to its potential for addiction.
History[edit]
Phenmetrazine was first patented in Germany in 1952 by Boehringer-Ingelheim, with some pharmacological data appearing in the literature in 1954. It was the result of a search by the company for an anorectic drug to replace amphetamine, which was increasingly subject to abuse.
Pharmacology[edit]
Phenmetrazine acts as a norepinephrine-dopamine releasing agent (NDRA). It is also a metabolite of phendimetrazine, a more complex drug. Phenmetrazine stimulates the brain, increases heart rate, blood pressure and decreases appetite. Its effects can last from 3 to 4 hours.
Side Effects[edit]
Side effects of phenmetrazine include insomnia, hyperactivity, and restlessness. It can also cause palpitations, sweating, and dizziness. In severe cases, it can lead to psychosis.
Legal Status[edit]
Phenmetrazine is a controlled substance in many countries due to its potential for addiction. It is a Schedule II controlled substance in the United States.
See Also[edit]
References[edit]
<references />


